Cipla is currently trading at Rs. 393.70, up by 2.95 points or 0.75% from its previous closing of Rs. 390.75 on the BSE.
The scrip opened at Rs. 394.55 and has touched a high and low of Rs. 395.45 and Rs. 391.10 respectively. So far 89028 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 395.45 on 08-Sep-2012 and a 52 week low of Rs. 275.60 on 19-Sep-2011.
Last one week high and low of the scrip stood at Rs. 395.45 and Rs. 371.80 respectively. The current market cap of the company is Rs. 31550.79 crore.
The promoters holding in the company stood at 36.80% while Institutions and Non-Institutions held 34.23% and 28.73% respectively.
Pharma major, Cipla has won a landmark patent case against Swiss drug maker F Hoffmann-La Roche in the Delhi High Court on September 7, 2012 over the Indian company’s generic copy of lung cancer drug Tarceva after a four-year court battle.
As per the Delhi High Court, Cipla's drug - Erlocip did not violate the Roche patent on its anti-lung cancer medication Tarceva due to its different molecular make-up. Justice Manmohan Singh observed in his 280-page judgment that it had been scientifically proven that Cipla’s generic version was a polymorph B variant of Roche’s patented drug and that it didn’t actually infringe any patent in India.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1464.85 |
Dr. Reddys Lab | 5955.65 |
Cipla | 1477.15 |
Zydus Lifesciences | 1050.35 |
Lupin | 1603.55 |
View more.. |